The NHS’s S2 scheme is often presented as a way for British patients to receive planned treatment in Europe at the NHS’s expense. In theory, it sounds like an attractive alternative for people waiting months—or even years—for hip, knee, shoulder, ACL or spinal surgery. In reality, however, the figures tell a very different story. While the scheme undoubtedly exists, the number of people using it has collapsed to just a few hundred a year, raising an obvious question: if it is such a valuable route, why is almost nobody using it?
On the face of it, the S2 scheme appears straightforward.
It allows eligible NHS patients to receive planned treatment in another European country, with the UK Government paying the foreign public healthcare system. For anyone frustrated by lengthy NHS waiting lists, that sounds almost too good to be true.
Unfortunately, it largely is.
The reality is that the S2 scheme is surrounded by so many conditions, restrictions and administrative hurdles that it has become a route used by remarkably few patients.
The first limitation is that S2 is not a route into Europe’s private hospitals.
The treatment must normally be provided through the destination country’s public healthcare system, and the foreign hospital must be willing to accept S2 funding arrangements. Many of Europe’s leading private hospitals, including those accredited by My Medical Gateway (MMG), are therefore outside the scope of the scheme.
Secondly, patients cannot simply decide they would prefer to have treatment abroad.
The NHS must first agree that the same treatment cannot be provided within what it considers to be a “medically justifiable” timescale. That is a clinical judgement, not simply a question of how long the waiting list happens to be. A patient may have been waiting many months for a knee replacement or spinal operation, yet still fail to qualify if the NHS concludes that the delay is clinically acceptable in their particular case.
The bureaucracy does not stop there.
Patients must identify a suitable hospital abroad, establish that it participates in the relevant public healthcare system, confirm that it will accept S2 funding, obtain medical information from the overseas provider, secure estimates and treatment details, complete the application process and then wait for authorisation before treatment can begin.
Unless someone already understands the system and knows exactly how to navigate it, this is an exceptionally difficult process.
That perhaps explains why so few people actually use it.
The latest official figures published by the Department of Health and Social Care show that the number of UK-issued S2 certificates has fallen dramatically.
In 2019, before Brexit and the pandemic, 1,356 certificates were issued.
By 2021 the figure had fallen to 740.
In 2022 it fell again to 610.
By 2023, only 224 certificates were issued across the whole United Kingdom.
Against NHS waiting lists measured in millions of patients, these are statistically tiny numbers. If the S2 scheme were genuinely functioning as a practical alternative for British patients seeking faster treatment abroad, it would be reasonable to expect many thousands of people to be using it every year. Instead, the numbers have dwindled into the hundreds.
Ironically, many of the conditions most commonly treated through S2 are precisely the conditions affecting working people: trauma and orthopaedics, including hips, knees and osteoarthritis, together with neurosurgery involving spinal conditions.
These are exactly the patients who often need rapid treatment to return to work. Yet they are also the patients least likely to have the time, specialist knowledge or administrative support needed to navigate a complex international funding process.
This is where MMG offers a fundamentally different proposition. Rather than asking patients to negotiate NHS approval, identify an overseas public hospital, obtain advance funding and satisfy multiple eligibility criteria, MMG provides direct access to fixed-price consultant-led treatment packages at carefully accredited private hospitals across Europe.
Patients know the price in advance. They know where they will be treated. They receive dedicated English-speaking support throughout the process. Most importantly, they avoid becoming trapped in a bureaucratic system that, while perfectly genuine, has become so restrictive that only a tiny number of patients now appear able to benefit from it.
For patients waiting for a hip replacement, knee replacement, shoulder surgery, ACL reconstruction or spinal surgery, the evidence increasingly suggests that the S2 scheme is less a realistic pathway than an administrative curiosity.
It exists. But the numbers suggest that, for the overwhelming majority of patients, it is simply not a practical solution.
Waiting for a hip replacement?
If persistent hip pain is affecting your mobility, independence or ability to work, you don’t have to spend months—or even years—waiting for treatment.
Visit MMG to compare fixed-price Treatment Packages at carefully accredited hospitals across Europe, understand exactly what is included and discover how much you could save compared with private treatment in the UK.
Click here to explore Hip Replacement with MMG https://www.mymedicalgateway.com/orthopaedics/hip-surgery
Leave a Reply